MDSAP certified - Ready for product registration in Canada!
Bentley has achieved a major milestone in its international expansion with the successful completion of certification under the internationally recognized Medical Device Single Audit Program (MDSAP). The audit confirms the company's high-quality standards and establishes the regulatory basis for the registration of its products in Canada – a strategically important market for Bentley.
By fulfilling this regulatory requirement, Bentley can now take the first formal steps toward bringing its entire product portfolio to the Canadian market. The MDSAP certification is a prerequisite to start registration activities with Health Canada – and thus essential for any future product approvals in the country. It also strengthens Bentley's international competitiveness and enhances regulatory efficiency across key markets.
MDSAP is one of the key audit programs for medical device manufacturers and allows market approval in several countries, including Canada, the US, Brazil, Australia, and Japan, with just one quality audit. For Bentley, this certification not only opens the door to Canada but also streamlines audit processes globally.
Until now, Bentley products could only be made available in Canada through the Special Access Program, which requires single application by physicians and individual review by Health Canada. With MDSAP certification, Bentley can now submit regular applications for approval with the aim of rapid registration and full market launch. The goal is to make core products such as BeGraft, BeFlared, BeGraft PLUS, and BeBack available in the Canadian market in the near future.
“This certification is an essential step toward making our technologically advanced solutions available to an even wider range of physicians and patients,” said Christian Bader, CTO of Bentley. "Canada is a strategically important market for us. With MSDAP we now have a clear path to take the next steps in our international growth journey.”
MDSAP certification also brings clear advantages for markets such as Australia, Brazil, and the US, where Bentley is already active. The harmonized audit process reduces follow-up audits, saves resources, and helps the launch of future product innovations.
Media Contact Bentley
Nadja Atwaa
Corporate Communications
Mobile +49 151 14124552
E-Mail n.atwaa@bentley.global
Bentley Endovascular Group (“Bentley”) is a global medical technology company developing, manufacturing, and marketing implants and catheters for the endovascular treatment of peripheral vascular and aortic diseases. Bentley was founded in 2009 by the serial entrepreneur Lars Sunnanväder and inventor Milisav Obradovic in Hechingen, Germany, a centre for medical innovation. Built on a foundation of innovation, quality, and strong customer service, Bentley serves customers in more than 80 countries through direct and indirect sales. In 2024, the number of employees were around 480 in more than 10 countries with revenue amounting to EUR 97 million. Please find more information on group.bentley.global
About MDSAP The Medical Device Single Audit Program (MDSAP) was initiated by international health authorities, including Health Canada, the U.S. Food and Drug Administration (FDA), ANVISA (Brazil), TGA (Australia), and Japan's MHLW. The program enables compliance with the regulatory requirements of all participating countries with a single quality management audit. The aim is to offer manufacturers more efficient market access without compromising on quality and safety.
Customer service:
+49 7471 984 995 10
Bentley InnoMed GmbH
Lotzenäcker 3
72379 Hechingen / Germany
+49 7471 99 99-0
Customer service:
+1 770 295 2288
Bentley US Inc.
2220 Northmont Pkwy. Suite 250
Duluth, GA 30096 / USA
+1 770 295 2288